Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2Breast 2Tumor-Agnostic 1Thoracic 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 2Hot Flashes 1Depressive Disorder, Major 1Depression 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 265Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 145Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Escitalopram × Breast × Clear all
NCT04973930 2025-05-13

IPT

New York State Psychiatric Institute

Phase 3 Suspended
20 enrolled
Breast

Breast Neoplasms, Depressive Disorder, Major

NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡